Terug
50
Dagbereik
€ 16,67
€ 17,78
52-Weeksbereik
€ 10,42
€ 76,67
Volume
2.940.794
50D / 200D Gem.
€ 18,99
/
€ 20,15
Vorige Slotkoers
€ 16,69
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -2,6 | 0,4 |
| P/B | 1,6 | 2,9 |
| ROE % | -53,5 | 3,7 |
| Net Margin % | -32,5 | 3,8 |
| Rev Growth 5Y % | 33,0 | 10,0 |
| D/E | 0,9 | 0,2 |
Belangrijkste Punten
Revenue grew 33,03% annually over 5 years — strong growth
Earnings declined -403,27% over the past year
Negative free cash flow of -307,45M
PEG of 0,01 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 17,45%
Capital efficient — spends only 4,64% of revenue on capex
Groei
Revenue Growth (5Y)
33,03%
Revenue (1Y)15,58%
Earnings (1Y)-403,27%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-53,47%
ROIC-22,63%
Net Margin-32,45%
Op. Margin-29,92%
Veiligheid
Debt / Equity
0,91
Current Ratio2,32
Interest Coverage-67,60
Waardering
P/E Ratio
-2,61
P/B Ratio1,63
EV/EBITDAN/A
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 15,58% | Revenue Growth (3Y) | 32,97% |
| Earnings Growth (1Y) | -403,27% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 33,03% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 2,20B | Net Income (TTM) | -713,41M |
| ROE | -53,47% | ROA | -21,30% |
| Gross Margin | 59,90% | Operating Margin | -29,92% |
| Net Margin | -32,45% | Free Cash Flow (TTM) | -307,45M |
| ROIC | -22,63% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,91 | Current Ratio | 2,32 |
| Interest Coverage | -67,60 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | -2,61 | P/B Ratio | 1,63 |
| P/S Ratio | 0,85 | PEG Ratio | 0,01 |
| EV/EBITDA | N/A | Dividend Yield | 0,00% |
| Market Cap | 1,86B | Enterprise Value | 2,10B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2,20B | 1,90B | 1,24B | 933,01M | 701,89M |
| Net Income | -713,41M | 235,24M | -535,98M | -703,49M | -418,78M |
| EPS (Diluted) | -7,13 | 2,34 | -5,80 | -8,03 | -5,15 |
| Gross Profit | 1,32B | 1,58B | 1,09B | 793,02M | 604,84M |
| Operating Income | -657,77M | 218,08M | -267,82M | -536,20M | -459,71M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 3,35B | 3,96B | 3,26B | 3,13B | 3,15B |
| Total Liabilities | 2,21B | 2,44B | 2,41B | 2,74B | 2,22B |
| Shareholders' Equity | 1,14B | 1,53B | 859,34M | 384,95M | 928,01M |
| Total Debt | 1,04B | 1,34B | 1,40B | 1,62B | 1,15B |
| Cash & Equivalents | 801,28M | 1,10B | 428,43M | 966,78M | 2,12B |
| Current Assets | 2,54B | 3,07B | 2,58B | 2,56B | 2,60B |
| Current Liabilities | 1,10B | 731,68M | 653,66M | 619,60M | 452,73M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#181 of 616
Recente Activiteit
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026